

Jonathan Strosberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1631425/publications.pdf>

Version: 2024-02-01

84
papers

7,939
citations

101543

36
h-index

62596

80
g-index

86
all docs

86
docs citations

86
times ranked

6057
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors. <i>New England Journal of Medicine</i> , 2017, 376, 125-135.	27.0	2,206
2	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i> , The, 2016, 387, 968-977.	13.7	962
3	First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. <i>Cancer</i> , 2011, 117, 268-275.	4.1	647
4	Gastroenteropancreatic Neuroendocrine Tumors. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 471-487.	329.8	378
5	Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With ¹⁷⁷ Lu-Dotatate in the Phase III NETTER-1 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2578-2584.	1.6	276
6	Consensus on biomarkers for neuroendocrine tumour disease. <i>Lancet Oncology</i> , The, 2015, 16, e435-e446.	10.7	217
7	Improved Outcome With Cytoreduction Versus Embolization for Symptomatic Hepatic Metastases of Carcinoid and Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2006, 13, 572-581.	1.5	211
8	¹⁷⁷ Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1752-1763.	10.7	195
9	Survival and Prognostic Factor Analysis of 146 Metastatic Neuroendocrine Tumors of the Mid-Gut. <i>Neuroendocrinology</i> , 2009, 89, 471-476.	2.5	149
10	Relapse-Free Survival in Patients With Nonmetastatic, Surgically Resected Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2012, 256, 321-325.	4.2	134
11	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.	7.0	132
12	Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. <i>Human Pathology</i> , 2009, 40, 1262-1268.	2.0	126
13	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021, 146, 56-73.	2.8	120
14	Incidental Detection of Pancreatic Neuroendocrine Tumors: An Analysis of Incidence and Outcomes. <i>Annals of Surgical Oncology</i> , 2012, 19, 2932-2936.	1.5	114
15	Radionuclide Therapy for Neuroendocrine Tumors. <i>Current Oncology Reports</i> , 2017, 19, 9.	4.0	113
16	Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 1551-1556.	1.6	110
17	Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. <i>World Journal of Gastroenterology</i> , 2010, 16, 2963.	3.3	104
18	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. <i>Endocrine Connections</i> , 2016, 5, 174-187.	1.9	83

#	ARTICLE	IF	CITATIONS
19	Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2372-2382.	6.4	79
20	Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2015, 22, 1-9.	3.1	76
21	Neuroendocrine tumours of the small intestine. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 755-773.	2.4	75
22	Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: ^{RADIANT} lung subgroup analysis. <i>Cancer Science</i> , 2018, 109, 174-181.	3.9	72
23	A Review of Systemic and Liver-Directed Therapies for Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic Tract. <i>Cancer Control</i> , 2011, 18, 127-137.	1.8	71
24	¹⁷⁷Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1023-1031.	3.0	60
25	Metastatic carcinoid tumor to the ovary: A clinicopathologic analysis of seventeen cases. <i>Gynecologic Oncology</i> , 2007, 106, 65-68.	1.4	58
26	Survival and Prognostic Factor Analysis in Patients With Metastatic Pancreatic Endocrine Carcinomas. <i>Pancreas</i> , 2009, 38, 255-258.	1.1	54
27	A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. <i>Annals of Oncology</i> , 2012, 23, 2335-2341.	1.2	53
28	Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. <i>Current Treatment Options in Oncology</i> , 2017, 18, 14.	3.0	52
29	Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2021, 28, 161-172.	3.1	52
30	Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. <i>Lancet Oncology</i> , The, 2020, 21, e431-e443.	10.7	51
31	A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. <i>Cancer</i> , 2021, 127, 3194-3201.	4.1	48
32	An update on gastroenteropancreatic neuroendocrine tumors. <i>Oncology</i> , 2014, 28, 749-56, 758.	0.5	45
33	Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 93, 102141.	7.7	43
34	The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors. <i>Drugs</i> , 2015, 75, 847-858.	10.9	42
35	Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms. <i>Oncologist</i> , 2020, 25, e48-e52.	3.7	42
36	A phase II study of axitinib in advanced neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2016, 23, 411-418.	3.1	38

#	ARTICLE	IF	CITATIONS
37	Update on the Management of Unusual Neuroendocrine Tumors: Pheochromocytoma and Paraganglioma, Medullary Thyroid Cancer and Adrenocortical Carcinoma. <i>Seminars in Oncology</i> , 2013, 40, 120-133.	2.2	37
38	¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors. <i>New England Journal of Medicine</i> , 2017, 376, 1390-1392.	27.0	35
39	A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2013, 20, 383-390.	3.1	32
40	Outcomes of Therasphere Radioembolization for Colorectal Metastases. <i>Clinical Colorectal Cancer</i> , 2015, 14, 146-153.	2.3	32
41	Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 69-72.	5.0	30
42	A phase I/IIb study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. <i>European Journal of Cancer</i> , 2022, 169, 93-102.	2.8	30
43	Novel immunotherapy strategies for treatment of neuroendocrine neoplasms. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 54-54.	3.0	29
44	Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. <i>Current Opinion in Oncology</i> , 2016, 28, 359-366.	2.4	28
45	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. <i>JMIR Research Protocols</i> , 2019, 8, e11545.	1.0	27
46	RUNX1T1. <i>Pancreas</i> , 2011, 40, 627-633.	1.1	26
47	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2019, 9, 18614.	3.3	26
48	Effective Treatment of Locally Advanced Endocrine Tumors of the Pancreas with Chemoradiotherapy. <i>Neuroendocrinology</i> , 2007, 85, 216-220.	2.5	24
49	Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3655.	2.4	23
50	Treatment of Metastatic Neuroendocrine Tumors of the Thymus with Capecitabine and Temozolomide: A Case Series. <i>Neuroendocrinology</i> , 2013, 97, 318-321.	2.5	20
51	A phase I/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2021, 124, 1803-1808.	6.4	20
52	TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. <i>Oncologist</i> , 2019, 24, 1446-1452.	3.7	19
53	Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances. <i>Journal of Nuclear Medicine</i> , 2019, 60, 721-727.	5.0	15
54	A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2020, 110, 377-383.	2.5	15

#	ARTICLE	IF	CITATIONS
55	Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell Hyperplasia. <i>Chest</i> , 2020, 158, 401-405.	0.8	15
56	Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. <i>Oncologist</i> , 2021, 26, 115-119.	3.7	15
57	Chemotherapy in Neuroendocrine Tumors. <i>Cancers</i> , 2021, 13, 4872.	3.7	13
58	Surgical Treatment of an Isolated Metastatic Myocardial Neuroendocrine Tumor. <i>Annals of Thoracic Surgery</i> , 2016, 101, 747-749.	1.3	11
59	Evolving Treatment Strategies for Management of Carcinoid Tumors. <i>Current Treatment Options in Oncology</i> , 2013, 14, 374-388.	3.0	10
60	Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 292-299.	3.8	9
61	Somatostatin receptor radionuclide therapy in neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2021, 28, R81-R93.	3.1	9
62	Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 2966.	3.7	9
63	Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors. <i>Current Oncology</i> , 2022, 29, 510-515.	2.2	8
64	Peptide Receptor Radiotherapy Comes of Age. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 615-625.	3.2	7
65	Partial Splenic Artery Embolization in 35 Cancer Patients: Results of a Single Institution Retrospective Study. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 584-591.	0.5	7
66	Molecular imaging and radionuclide therapy of neuroendocrine tumors. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 16-21.	2.3	7
67	Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. <i>JCO Oncology Practice</i> , 2021, 17, 607-614.	2.9	7
68	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1094-1095.	5.0	6
69	Sensitivity and Specificity of the NETest: A Validation Study. <i>Neuroendocrinology</i> , 2021, 111, 580-585.	2.5	6
70	Markers of Systemic Inflammation in Neuroendocrine Tumors. <i>Pancreas</i> , 2021, 50, 130-137.	1.1	6
71	Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review. <i>Cancers</i> , 2022, 14, 1428.	3.7	6
72	External beam irradiation of myocardial carcinoid metastases: a case report. <i>Journal of Medical Case Reports</i> , 2007, 1, 95.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Comparison of Nausea and Vomiting Associated With Amino Acid Formulations Coinfused With Peptide Receptor Radionuclide Therapy. <i>Pancreas</i> , 2021, 50, 513-515.	1.1	5
74	Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is It an Either/Or Question?. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1669-1671.	5.0	5
75	Pancreatic NETs: where do we stand now?. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 361-366.	5.9	4
76	Desmoplastic mesenteric lesions do not respond radiographically to peptide receptor radionuclide therapy. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12936.	2.6	3
77	An Update on the Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH). <i>Current Treatment Options in Oncology</i> , 2021, 22, 28.	3.0	3
78	Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency. <i>Pancreas</i> , 2020, 49, 408-412.	1.1	2
79	What is the role of checkpoint inhibitors in neuroendocrine neoplasms?. <i>Oncotarget</i> , 2020, 11, 3751-3752.	1.8	2
80	Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1321-1321.	5.0	1
81	Congenital Anomaly Detected During Work-up of Cystic Pancreatic Lesion. <i>Gastroenterology</i> , 2015, 149, 33-34.	1.3	0
82	Management of NETs in the Precision Medicine Era. , 2019, , 575-589.		0
83	Radioembolization for Metastatic Neuroendocrine Tumors. <i>Digestive Disease Interventions</i> , 0, 05, .	0.2	0
84	Multiple Tumors in a Young Patient. <i>Gastroenterology</i> , 2022, 163, e13-e15.	1.3	0